Shanghai Nianxing Industrial Co., Ltd
China
Product Name: NEDOCROMIL SODIUM
Price: Check
Purity: 98.0%
Stocking Period: 10 Day
Contact: Yang
Email: sales@echemcloud.com

69049-74-7

69049-74-7 structure

69049-74-7 structure

Name: NEDOCROMIL SODIUM
Chemical Name: nedocromil sodium
CAS Number: 69049-74-7
Molecular Formula: C₁₉H₁₅NNa₂O₇
Molecular Weight: 415.30400
Catalog: Signaling Pathways GPCR/G Protein Histamine Receptor
Create Date: 2018-05-09 08:00:00
Modify Date: 2025-08-25 09:15:56
Nedocromil sodium suppresses the action or formation of multiple mediators, including histamine, leukotriene C4 (LTC4), and prostaglandin D2 (PGD2).

Name	nedocromil sodium
Synonyms	Nedocromil sodium (USAN) Tilarin disodium 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano[3,2-g]-quinoline-2,8-dicarboxylate dissodium 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano<3,2-g>quinoline-2,8-dicarboxylate 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano[3,2-g]quinoline-2,8-dicarboxylic acid disodium salt Alocril disodium,9-ethyl-4,6-dioxo-10-propylpyrano[3,2-g]quinoline-2,8-dicarboxylate Nedocromil sodium UNII-ET8IF4KS1T disodium 9-ethyl-4,6-dioxo-10-propyl-4H,6H pyrano[3,2-g]quinoline-2,8-dicarboxylate di-sodium 9-ethyl-4,6-dioxo-10-propyl-4H,6H-pyrano[3,2-g]quinoline-2,8-dicarboxylic trihydrate Tilade

Description	Nedocromil sodium suppresses the action or formation of multiple mediators, including histamine, leukotriene C4 (LTC4), and prostaglandin D2 (PGD2).
Related Catalog	Signaling Pathways >> GPCR/G Protein >> Histamine Receptor Signaling Pathways >> Immunology/Inflammation >> Histamine Receptor Signaling Pathways >> GPCR/G Protein >> Leukotriene Receptor Signaling Pathways >> GPCR/G Protein >> Prostaglandin Receptor Research Areas >> Inflammation/Immunology
Target	Histamine LTC4 PGD2
In Vitro	Nedocromil inhibits the release of histamine, LTC4, and PGD2 from mast cells challenged with antigen (with IC30 values of 2.1 μM, 2.3 μM, and 1.9 μM, respectively) and with anti-human IgE (IC30 values of 4.7 μM, 1.3 μM, and 1.3 μM, respectively)[1].
In Vivo	Nedocromil-treated diabetic mice show significantly improved heart function compared with controls. The contractility and relaxation forces show similar improvements. However, the cardiac function of Nedocromil-treated diabetic mice remains significantly impaired when compared with normal mice. Nedocromil can significantly improve cardiac function in mice with diabetic cardiomyopathy, but the treatment cannot restore normal function[2].
Animal Admin	Mice[2] 8-12 weeks old C57/BL6 male mice between 23-25 g receive intraperitoneal (i.p.) injections of 50 mg/kg Streptozotocin (STZ), dissolved in 100 mM citrate buffer pH 4.5, for five consecutive days. Diabetic mice (13-week-old) are randomly divided into three groups: 1) untreated group; 2) Nedocromil group, with Nedocromil released at the rate of 30 mg/kg per day from a subcutaneous (s.c.) pellet implantation; and vehicle group, with an inactive pellet implanted. Normal mice (non-diabetic) and normal mice that receive Nedocromil (30 mg/kg per day) are also included in this study for comparison. All sample groups included 15 mice (n=15)[2].
References	[1]. Wells E, et al. Characterization of primate bronchoalveolar mast cells. II. Inhibition of histamine, LTC4, and PGD2 release from primate bronchoalveolar mast cells and a comparison with rat peritoneal mastcells. J Immunol. 1986 Dec 15;137(12):3941-5. [2]. Myocardial remodeling in diabetic cardiomyopathy associated with cardiac mast cell activation. Huang ZG, et al. PLoS One. 2013;8(3):e60827.

Boiling Point	645.5ºC at 760 mmHg
Molecular Formula	C₁₉H₁₅NNa₂O₇
Molecular Weight	415.30400
Flash Point	344.2ºC
Exact Mass	415.06400
PSA	132.47000
Storage condition	2-8°C

RIDADR	NONH for all modes of transport

Precursor 9
588-16-9 98331-45-4 98331-43-2 98331-47-6
69049-62-3 69049-63-4 69049-64-5 69049-70-3
69049-68-9
DownStream 0

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.